InsiderClue
Stocks · Health care · Surgical & Medical Instruments & Apparatus

KESTRA MEDICAL TECHNOLOGIES, LTD.

KMTS Clue Score63
United States Fiscal year ends April CIK 0001877184
$26.98 +4.70% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $26.98 +14.86% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 6 Mar 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2024Revenue27.8Operating income−85.1Net income−94.1EPS, diluted−5.07Fiscal year 2025Revenue59.8 +115.1%Operating income−106.4Net income−113.8EPS, diluted−5.13Fiscal year 2026Revenue95.1 +59.0%Operating income−134.7Net income−131.6EPS, diluted−2.43
FY2024FY2025FY2026
Revenue 27.8 59.8 95.1
Growth +115.1% +59.0%
Operating income −85.1 −106.4 −134.7
Net income −94.1 −113.8 −131.6
Growth
EPS, diluted −5.07 −5.13 −2.43

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2024Gross margin1.3%Operating margin−305.8%Net margin−338.4%Free cash flow margin−303.7%Fiscal year 2025Gross margin40.5%Operating margin−177.8%Net margin−190.3%Free cash flow margin−168.1%Fiscal year 2026Gross margin51.4%Operating margin−141.6%Net margin−138.4%Free cash flow margin−122.6%
FY2024FY2025FY2026
Gross margin 1.3% 40.5% 51.4%
Operating margin −305.8% −177.8% −141.6%
Net margin −338.4% −190.3% −138.4%
Free cash flow margin −303.7% −168.1% −122.6%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2024Operating cash flow−72.2Capital expenditure−12.2Free cash flow−84.5Fiscal year 2025Operating cash flow−77.6Capital expenditure−22.9Free cash flow−100.5Fiscal year 2026Operating cash flow−81.7Capital expenditure−34.9Free cash flow−116.6
FY2024FY2025FY2026
Operating cash flow −72.2 −77.6 −81.7
Capital expenditure −12.2 −22.9 −34.9
Free cash flow −84.5 −100.5 −116.6
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2024Cash8.2Total debt42.5Net cash (debt)−34.3Shareholders’ equity−209.4Fiscal year 2025Cash237.6Total debt41.1Net cash (debt)196.5Shareholders’ equity205.4Debt to equity0.20Fiscal year 2026Cash99.7Total debt42.6Net cash (debt)57.1Shareholders’ equity259.7Debt to equity0.16
FY2024FY2025FY2026
Cash 8.2 237.6 99.7
Total debt 42.5 41.1 42.6
Net cash (debt) −34.3 196.5 57.1
Shareholders’ equity −209.4 205.4 259.7
Debt to equity n/a 0.20 0.16

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2026 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending April, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2024 30 Apr 2024 FY2025 30 Apr 2025 FY2026† 30 Apr 2026
Revenue and profit
27.8 59.8 95.1
Growth +115.1% +59.0%
27.5 35.6 46.3
0.4 24.2 48.9
Growth +6,587.8% +101.8%
15.5 15.7 19.5
69.9 114.9 164.1
−85.1 −106.4 −134.7
Growth
−94.1 −113.7 −131.3
0.0 0.1 0.3
−94.1 −113.8 −131.6
Growth
Per share
−5.07 −5.13 −2.43
−5.07 −5.13 −2.43
Growth
19.9 24.6 54.2
19.9 24.6 54.2
Growth +23.6% +120.4%

† The diluted share count jumps at 2026, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 3 of 3 years on file.